Item 7.01 Regulation FD Disclosure




The registration statement on Form 10 filed by Biohaven Ltd. with the Securities
and Exchange Commission ("SEC") in connection with the previously announced
spin-off by Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") of
Biohaven Ltd. became effective on September 22, 2022. Biohaven Ltd. will own the
Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and
myostatin inhibition platforms, preclinical product candidates, and certain
corporate infrastructure currently owned by Biohaven.

Biohaven Ltd. common shares will begin trading today, September 23, 2022, on a
"when-issued" basis on the New York Stock Exchange under the symbol "BHVN WI"
and under "Biohaven Ltd." "When-issued" trading of Biohaven Ltd. common shares
will continue until the spin-off occurs. The distribution date for the spin-off
is expected to be early in the fourth quarter of 2022, subject to the closing
conditions noted in Biohaven's Proxy Statement filed with the SEC on August 30,
2022, including receipt of shareholder approval at Biohaven's special meeting of
shareholders to be held on September 29, 2022. The CUSIP number for Biohaven
Ltd. common shares will be G1110E 107.

The information set forth in this Item 7.01 of this Current Report on Form 8-K
is being furnished and shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall
it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

      Exhibit Number                                      Exhibit Description

           104                   The cover page of this Current Report on Form 8-K formatted as Inline
                                 XBRL.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses